Details of the Drug Combination

General Information of Drug Combination (ID: DC8F2FW)

Drug Combination Name
LIAROZOLE Pentostatin
Indication
Disease Entry Status REF
Lung adenocarcinoma Investigative [1]
Component Drugs LIAROZOLE   DM4OYXE Pentostatin   DM0HXDS
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: NCI-H522
Zero Interaction Potency (ZIP) Score: 2.84
Bliss Independence Score: 3.71
Loewe Additivity Score: 1.39
LHighest Single Agent (HSA) Score: 2.16

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of LIAROZOLE
Disease Entry ICD 11 Status REF
Dermatological disease DA24.Y Phase 2/3 [2]
LIAROZOLE Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [5]
Cytochrome P450 26 (CYP26A1) TTD7Q0R CP26A_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Indication(s) of Pentostatin
Disease Entry ICD 11 Status REF
Acute graft versus host disease 4B24.0 Approved [3]
Hairy cell leukaemia 2A82.2 Approved [4]
Leukemia N.A. Approved [3]
Pentostatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adenosine deaminase (ADA) TTLP57V ADA_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Childhood T acute lymphoblastic leukemia DCBV33M CCRF-CEM Investigative [8]
Chronic myelogenous leukemia DC15S25 K-562 Investigative [8]
Renal cell carcinoma DCYCVQP SN12C Investigative [8]
Breast adenocarcinoma DC3DPOZ MDA-MB-468 Investigative [9]
Colon carcinoma DC14P0Q KM12 Investigative [9]
Invasive ductal carcinoma DCBX66D BT-549 Investigative [9]
Adenocarcinoma DCQS4H1 A549 Investigative [1]
Adenocarcinoma DCXHG8X HCT116 Investigative [1]
Lung adenocarcinoma DCO61GR HOP-62 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5210).
3 Pentostatin FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4805).
5 Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
6 Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem. 2008 Sep 1;16(17):8301-13.
7 Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.
8 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
9 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165